Vertex Pharmaceuticals Inc
VRTX462.130USD
+5.260+1.15%
Fechamento 08/01, 16:00（ET）Cotações atrasadas em 15 min
118.75BValor de mercado
PerdaP/L TTM
Mais detalhes de Vertex Pharmaceuticals Inc Empresa
Vertex Pharmaceuticals Incorporated is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has seven approved medicines: five that treat the underlying cause of cystic fibrosis (CF), one that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT), and one that treats moderate-to-severe acute pain. Its pipeline includes clinical-stage programs in CF, SCD, beta thalassemia, acute and peripheral neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy and other autoimmune renal diseases and cytopenias, type 1 diabetes, myotonic dystrophy type 1, and autosomal dominant polycystic kidney disease. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (elexacaftor/tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor), and KALYDECO (ivacaftor).
Informações da empresa
Código da empresaVRTX
Nome da EmpresaVertex Pharmaceuticals Inc
Data de listagemJul 24, 1991
Fundado em1989
CEODr. Reshma Kewalramani
Número de funcionários6100
Tipo de títulosOrdinary Share
Fim do ano fiscalJul 24
Endereço50 Northern Avenue
CidadeBOSTON
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal02210
Telefone16173416393
Sitehttps://www.vrtx.com/
Código da empresaVRTX
Data de listagemJul 24, 1991
Fundado em1989
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Reshma Kewalramani
Dr. Reshma Kewalramani
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
41.81K
+38.72%
Mr. Bruce I. Sachs
Mr. Bruce I. Sachs
Lead Independent Director
Lead Independent Director
40.00K
--
Dr. Carmen Bozic, M.D.
Dr. Carmen Bozic, M.D.
Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer
Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer
32.67K
+40.46%
Dr. Ourania (Nia) Tatsis, Ph.D.
Dr. Ourania (Nia) Tatsis, Ph.D.
Executive Vice President, Chief Regulatory and Quality Officer
Executive Vice President, Chief Regulatory and Quality Officer
30.30K
+19.95%
Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.
Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
24.47K
--
Mr. Jonathan Biller, J.D.
Mr. Jonathan Biller, J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
17.61K
+5.74%
Mr. Duncan Mckechnie
Mr. Duncan Mckechnie
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
16.13K
--
Mr. Lloyd A. Carney
Mr. Lloyd A. Carney
Independent Director
Independent Director
7.12K
+12.60%
Dr. Sangeeta N. Bhatia, M.D., Ph.D.
Dr. Sangeeta N. Bhatia, M.D., Ph.D.
Independent Director
Independent Director
4.83K
+8.93%
Ms. Jennifer J. Schneider
Ms. Jennifer J. Schneider
Independent Director
Independent Director
1.72K
+86.33%
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Reshma Kewalramani
Dr. Reshma Kewalramani
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
41.81K
+38.72%
Mr. Bruce I. Sachs
Mr. Bruce I. Sachs
Lead Independent Director
Lead Independent Director
40.00K
--
Dr. Carmen Bozic, M.D.
Dr. Carmen Bozic, M.D.
Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer
Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer
32.67K
+40.46%
Dr. Ourania (Nia) Tatsis, Ph.D.
Dr. Ourania (Nia) Tatsis, Ph.D.
Executive Vice President, Chief Regulatory and Quality Officer
Executive Vice President, Chief Regulatory and Quality Officer
30.30K
+19.95%
Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.
Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
24.47K
--
Mr. Jonathan Biller, J.D.
Mr. Jonathan Biller, J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
17.61K
+5.74%
Detalhamento da receita
Moeda: USDAtualizado em: dom, 6 de jul
Moeda: USDAtualizado em: dom, 6 de jul
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Por EmpresaUSD
Nome
Receita
Proporção
TRIKAFTA
2.54B
91.86%
Other product revenues
156.60M
5.67%
ALYFTREK
53.90M
1.95%
CASGEVY
14.20M
0.51%
Por RegiãoUSD
Nome
Receita
Proporção
United States
1.65B
59.91%
Europe
826.60M
29.95%
Other
280.10M
10.15%
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
TRIKAFTA
2.54B
91.86%
Other product revenues
156.60M
5.67%
ALYFTREK
53.90M
1.95%
CASGEVY
14.20M
0.51%
Distribuição de ações
Atualizado em: qui, 15 de mai
Atualizado em: qui, 15 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Capital World Investors
11.11%
The Vanguard Group, Inc.
9.10%
Capital Research Global Investors
5.66%
BlackRock Institutional Trust Company, N.A.
5.45%
State Street Global Advisors (US)
4.59%
Other
64.08%
Investidores
Investidores
Proporção
Capital World Investors
11.11%
The Vanguard Group, Inc.
9.10%
Capital Research Global Investors
5.66%
BlackRock Institutional Trust Company, N.A.
5.45%
State Street Global Advisors (US)
4.59%
Other
64.08%
Tipos de investidores
Investidores
Proporção
Investment Advisor
59.72%
Investment Advisor/Hedge Fund
28.09%
Research Firm
2.55%
Pension Fund
2.35%
Bank and Trust
2.04%
Sovereign Wealth Fund
1.44%
Hedge Fund
1.29%
Insurance Company
0.16%
Individual Investor
0.14%
Other
2.22%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
2926
251.46M
97.92%
+1.75M
2025Q1
2977
252.24M
98.22%
-39.54K
2024Q4
2877
248.76M
96.87%
-2.25M
2024Q3
2786
247.87M
96.18%
-4.19M
2024Q2
2747
248.36M
96.27%
-4.14M
2024Q1
2680
247.63M
95.87%
-4.48M
2023Q4
2608
247.92M
96.20%
-4.51M
2023Q3
2477
248.64M
96.45%
-6.19M
2023Q2
2488
248.89M
96.55%
-7.11M
2023Q1
2468
250.11M
97.13%
-4.74M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Capital World Investors
28.53M
11.11%
+207.61K
+0.73%
Mar 31, 2025
The Vanguard Group, Inc.
23.38M
9.1%
+232.41K
+1.00%
Mar 31, 2025
Capital Research Global Investors
14.54M
5.66%
+4.11M
+39.38%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
14.00M
5.45%
-330.35K
-2.31%
Mar 31, 2025
State Street Global Advisors (US)
11.79M
4.59%
-190.75K
-1.59%
Mar 31, 2025
Fidelity Management & Research Company LLC
7.62M
2.97%
-1.49M
-16.32%
Mar 31, 2025
Jennison Associates LLC
5.06M
1.97%
+744.68K
+17.25%
Mar 31, 2025
Geode Capital Management, L.L.C.
5.76M
2.24%
+113.52K
+2.01%
Mar 31, 2025
Wellington Management Company, LLP
5.45M
2.12%
-461.34K
-7.80%
Mar 31, 2025
Invesco Capital Management (QQQ Trust)
5.31M
2.07%
-20.76K
-0.39%
Jun 30, 2025
Ver Mais
ETFs Relacionados
Atualizado em: há 48 minutos
Atualizado em: há 48 minutos
Nome
Proporção
VanEck Biotech ETF
10.59%
Tema Neuroscience and Mental Health ETF
10.48%
ProShares Ultra Nasdaq Biotechnology
7.77%
Invesco Nasdaq Biotechnology ETF
7.77%
iShares Biotechnology ETF
6.83%
Invesco Biotechnology & Genome ETF
4.86%
Natixis Loomis Sayles Focused Growth ETF
4.46%
Franklin Genomic Advancements ETF
4.34%
Global X Genomics & Biotechnology ETF
3.55%
Tema Heart & Health ETF
3.25%
Ver Mais
VanEck Biotech ETF
Proporção10.59%
Tema Neuroscience and Mental Health ETF
Proporção10.48%
ProShares Ultra Nasdaq Biotechnology
Proporção7.77%
Invesco Nasdaq Biotechnology ETF
Proporção7.77%
iShares Biotechnology ETF
Proporção6.83%
Invesco Biotechnology & Genome ETF
Proporção4.86%
Natixis Loomis Sayles Focused Growth ETF
Proporção4.46%
Franklin Genomic Advancements ETF
Proporção4.34%
Global X Genomics & Biotechnology ETF
Proporção3.55%
Tema Heart & Health ETF
Proporção3.25%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
